Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Etrumadenant. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A known ✓ | P29274 | 20/20 | 1.00 |
| ▸ | ADORA2B known ✓ | P29275 | 17/20 | 1.00 |
| ▸ | ADORA1 | P30542 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Etrumadenant SCHEMBL29560949 | 1.00 | ADORA2A (1.00) | ADORA2AADORA2BADORA1 | |
| Etrumadenant SCHEMBL29659112 | 1.00 | ADORA2A (1.00) | ADORA2AADORA2BADORA1 | |
| Etrumadenant SCHEMBL20401465 | 1.00 | ADORA2A (1.00) | ADORA2AADORA2BADORA1 | |
| Etrumadenant SCHEMBL29653560 | 0.94 | ADORA2A (0.89) | ADORA2AADORA2BADORA1 | |
| SCHEMBL20417111 | 0.93 | ADORA2A (0.87) | ADORA2AADORA2BADORA1 | |
| SCHEMBL20401123 | 0.91 | ADORA2A (0.83) | ADORA2AADORA2BADORA1 | |
| SCHEMBL20436497 | 0.91 | ADORA2A (0.83) | ADORA2AADORA2BADORA1 | |
| SCHEMBL20401417 | 0.91 | ADORA2A (0.83) | ADORA2AADORA2BADORA1 | |
| SCHEMBL20401229 | 0.89 | ADORA2A (0.80) | ADORA2AADORA2BADORA1 | |
| SCHEMBL20417122 | 0.89 | ADORA2A (0.79) | ADORA2AADORA2BADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 741 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4735445-A1 | KRAS MODULATING COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2026-05-06 | — | — | EP | claimed |
| EP-4735453-A1 | KRAS MODULATING COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2026-05-06 | — | — | EP | claimed |
| US-20260115190-A1 | DISPERSIONS OF ETRUMADENANT | ARCUS BIOSCIENCES INC (US) | 2026-04-30 | — | — | US | claimed |
| EP-4720055-A1 | CBL-B INHIBITORS AND METHODS OF USE THEREOF | Arcus Biosciences, Inc. (US) | 2026-04-08 | — | — | EP | claimed |
| EP-4705292-A1 | CBL-B INHIBITORS AND METHODS OF USE THEREOF | Arcus Biosciences, Inc. (US) | 2026-03-11 | — | — | EP | claimed |
| EP-4695260-A1 | KRAS MODULATING COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2026-02-18 | — | — | EP | claimed |
| EP-4604920-A1 | LYOPHILIZED FORMULATIONS OF CD73 COMPOUNDS | Arcus Biosciences, Inc. (US) | 2025-08-27 | — | — | EP | claimed |
| EP-4602041-A1 | HPK1 INHIBITORS AND METHODS OF USE THEREOF | Arcus Biosciences, Inc. (US) | 2025-08-20 | — | — | EP | claimed |
| EP-4558501-A1 | CBL-B INHIBITORS AND METHODS OF USE THEREOF | Arcus Biosciences, Inc. (US) | 2025-05-28 | — | — | EP | claimed |
| US-20250161312-A1 | A METHOD FOR THE TREATMENT OF CHEMOTHERAPEUTIC DRUG-INDUCED NEPHROTOXICITY | Institut National de la Santé et de la Recherche Médicale (FR) | 2025-05-22 | — | — | US | claimed |
| WO-2022204438-A1 | TARGETED THERAPIES IN CANCER | ONCXERNA THERAPEUTICS, INC. (US) | 2022-09-29 | — | — | WO | claimed |
| CN-115087488-A | Antibodies and fusion proteins binding to CCR8 and uses thereof | 震动疗法股份有限公司 | 2022-09-20 | — | — | CN | claimed |
| EP-4055609-A1 | CLASSIFICATION OF TUMOR MICROENVIRONMENTS | Oncxerna Therapeutics, Inc. (US) | 2022-09-14 | — | — | EP | claimed |
| WO-2022185742-A1 | PROPHYLACTIC OR THERAPEUTIC COMPOSITION FOR DISSEMINATED INTRAVASCULAR COAGULATION SYNDROME | 学校法人埼玉医科大学 | 2022-09-09 | — | — | WO | claimed |
| WO-2022162569-A1 | DOSAGE REGIMES FOR ANTI-CD73 AND ANTI-ENTPD2 ANTIBODIES AND USES THEREOF | NOVARTIS AG (CH) | 2022-08-04 | — | — | WO | claimed |
| EP-4031248-A1 | COMBINATION THERAPY WITH ENTPD2 AND CD73 ANTIBODIES | Novartis AG (CH) | 2022-07-27 | — | — | EP | claimed |
| CN-114556480-A | Classification of tumor microenvironments | 欧森纳治疗股份有限公司 | 2022-05-27 | — | — | CN | claimed |
| WO-2022101619-A1 | A MYCOBACTERIUM FOR USE IN CANCER THERAPY | IMMODULON THERAPEUTICS LIMITED (GB) | 2022-05-19 | — | — | WO | claimed |
| CN-114502589-A | Combination therapy with ENTPD2 and CD73 antibodies | 诺华股份有限公司 | 2022-05-13 | — | — | CN | claimed |
| WO-2022096896-A1 | MYCOBACTERIAL IMMUNOTHERAPY FOR TREATING CANCER | IMMODULON THERAPEUTICS LIMITED (GB) | 2022-05-12 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260115190-A1 | DISPERSIONS OF ETRUMADENANT | ADORA2A, ADORA3, ADORA1 | ADORA2A 1/4885ADORA2B 38/4885ADORA1 3/4885 |
| US-20250161312-A1 | A METHOD FOR THE TREATMENT OF CHEMOTHERAPEUTIC DRUG-INDUCED NEPHROTOXICITY | ADORA2A, ADORA3, ADORA2B | ADORA2A 1/4885ADORA2B 3/4885ADORA1 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.